141 related articles for article (PubMed ID: 10850451)
1. p53 transdominance but no gain of function in mouse brain tumor model.
Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
[TBL] [Abstract][Full Text] [Related]
2. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.
Klein MA; Rüedi D; Nozaki M; Dell EW; Diserens AC; Seelentag W; Janzer RC; Aguzzi A; Hegi ME
Oncogene; 2000 Nov; 19(47):5329-37. PubMed ID: 11103934
[TBL] [Abstract][Full Text] [Related]
3. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
5. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
7. Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region.
White MK; Skowronska A; Gordon J; Del Valle L; Deshmane SL; Giordano A; Khalili K
Anticancer Res; 2006; 26(6B):4079-92. PubMed ID: 17201119
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
[TBL] [Abstract][Full Text] [Related]
9. The p53 gene and its role in human brain tumors.
Bögler O; Huang HJ; Kleihues P; Cavenee WK
Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
[TBL] [Abstract][Full Text] [Related]
10. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
11. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
12. The differential effects of mutant p53 alleles on advanced murine lung cancer.
Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T
Cancer Res; 2005 Nov; 65(22):10280-8. PubMed ID: 16288016
[TBL] [Abstract][Full Text] [Related]
13. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW
Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766
[TBL] [Abstract][Full Text] [Related]
14. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
Adhikari AS; Iwakuma T
Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
[TBL] [Abstract][Full Text] [Related]
16. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions.
Inga A; Nahari D; Velasco-Miguel S; Friedberg EC; Resnick MA
Oncogene; 2002 Aug; 21(37):5704-15. PubMed ID: 12173040
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
18. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
[TBL] [Abstract][Full Text] [Related]
19. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
20. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells.
Ridgeway AG; McMenamin J; Leder P
Oncogene; 2006 Jun; 25(25):3518-27. PubMed ID: 16434961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]